-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH Poster Walk on Time to Examine Time Toxicity in Hematology

Program: ASH Poster Walks
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, patient-reported outcomes, real-world evidence, Adverse Events, survivorship
Thursday, December 14, 2023: 5:00 PM-6:00 PM
(Virtual Program)
One unifying thread across classical and malignant hematology involves efforts to reduce "time toxicity." While specific definitions of time toxicity are still being established, the broad principle is clear: particularly for incurable diseases, patients often spend significant proportions of their days on healthcare-related interactions. While studies of reduced-frequency romiplostim in immune thrombocytopenic purpura (ITP) or teclistamab in myeloma clearly fit this definition, for example, so too do trials that seek to reduce transfusion dependence in myeloproliferative neoplasms (MPN) or lower the frequency of pain crises requiring Emergency Room visits in sickle-cell disease. Relevant studies also include interventions of decreased diagnostic monitoring and digital health tools to decrease patient time in clinic without compromising clinical outcomes. A concerted cross-disease poster walk focused on "time toxicity" will help the field understand how to define this concept broadly, how to design studies that address time toxicity (either directly through medication dosing frequency or indirectly by reducing healthcare resource utilization) and exploring the impact of time toxicity on patient quality of life.

Laurie Batchelder1*, Shawn X. Sun2*, Montserrat Casamayor3* and Ana María Rodríguez4*

1IQVIA, Reading, United Kingdom
2Takeda Development Center Americas, Inc., Cambridge, MA
3IQVIA, Barcelona, Spain
4IQVIA, Madrid, Spain

Melissa Shyian, MD* and Lauren Bolster, MD

University of Alberta, Edmonton, AB, Canada

Alaina M Kelly, MD1, Moniba Nazeef, MD1, Fauzia Osman, MPH1*, Shannon Stiles1*, Eva K. Allen, ANP, RN2*, Hayley Kiander, BSN, RN2*, Wendy Curran, MS, RN2* and Benjamin Schnapp, MS1*

1Department of Medicine, The University of Wisconsin-Madison, Madison, WI
2Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin Hospitals and Clinics, Madison, WI

Brooke Kania, DO1, David Awad, PharmD2*, Michael Kane, PharmD3*, Andrew M Evens, DO, MBA, MSc4 and Neil Palmisiano, MD, MS5

1Department of Medicine, Rutgers Robert Wood Johnson Medical School, Parsippany, NJ
2Department of Pharmacy, Robert Wood Johnson University Hospital, New Brunswick, NJ
3Department of Pharmacy, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
4Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
5Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

John L Vaughn, MD, MS1, Man-Yee Merl, PharmD, BCOP2*, Jensa C Morris, MD1* and Bonnie E Gould Rothberg, MD, PhD, MPH, MMM1*

1Smilow Hospitalist Service, Yale New Haven Hospital, New Haven, CT
2Smilow Cancer Hospital, Yale New Haven Hospital, New Haven, CT

Lucia Masarova, MD1, Tom Liu, MS2*, Mirko Fillbrunn, PhD3*, Weilong Li, PhD4*, Gautam Sajeev, D.Sc3*, Sumati Rao, PhD2*, Boris Gorsh, PharmD2* and James Signorovitch, PhD3*

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2GSK plc, Collegeville, PA
3Analysis Group, Boston, MA
4Analysis Group, New York, NY

See more of: ASH Poster Walks